OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast Cancer

November 15th 2023

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

Dr. Sabari on the EVOKE-02 Trial With Sacituzumab Govitecan in NSCLC

November 14th 2023

Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.

Dr Hochster on the Importance of Clinical Trial Participation in Cancer Care

November 14th 2023

Howard S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium.

Dr Levy on the Ongoing Development of TROP-2 ADCs in NSCLC

November 14th 2023

Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.

Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLC

November 14th 2023

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Dr Liu on the Benefits of Biomarker Testing in NSCLC

November 14th 2023

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

Dr Wakelee on the Implications of the TRUST-II Trial of Taletrectinib in ROS1+ NSCLC

November 13th 2023

Heather Wakelee, MD, FASCO, discusses the significance of early data on the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer from the phase 2 TRUST-II trial.

Dr Baretti on Mitigating Toxicities Associated With FGFR Inhibition in Cholangiocarcinoma

November 13th 2023

Marina Baretti, MD, discusses some common adverse effects associated with FGFR inhibition in patients with cholangiocarcinoma, as well as strategies to mitigate these AEs in clinical practice.

Dr Lazzaro on Lung Cancer Screening in High-Risk Individuals

November 12th 2023

Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.

Dr Haffty on Technical and Biological Advancements in Radiotherapy Within Breast Cancer

November 12th 2023

Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.

Dr Rohs on Pityriasis Rubra Pilaris as an Early Signal of Lung Cancer Recurrence

November 11th 2023

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

Dr Levy on Onco-Directed ADCs in NSCLC

November 11th 2023

Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

November 11th 2023

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.

Dr Tan on the Potential Utility of ctDNA in RCC

November 11th 2023

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

November 11th 2023

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

November 10th 2023

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

November 10th 2023

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

November 10th 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

November 10th 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

November 10th 2023

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.